Seven Eight Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Seven Eight Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-47,600	Closed	-$2.26M	–	783
2019 Q1	$2.26M	Buy	47,600 +35,400	+290%	+$1.56M	0.12%	225
2018 Q4	$440K	Sell	12,200 -14,300	-54%	-$671K	0.02%	441
2018 Q3	$1.63M	Buy	+26,500	New	+$1.7M	0.1%	288
2017 Q3	–	Sell	-5,600	Closed	-$294K	–	663
2017 Q2	$294K	Buy	+5,600	New	+$261K	0.04%	354

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Seven Eight Capital's AERI Position: Q2 2019 in Review

Seven Eight Capital sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 47,600 shares — an estimated $2.26M sold.

Seven Eight Capital first reported a position in AERI in Q2 2017 and held it in 4 quarters. The position peaked at $2.26M in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

Seven Eight Capital reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Seven Eight Capital sold 47,600 Aerie Pharmaceuticals shares in Q2 2019, an estimated $2.26M.
Seven Eight Capital first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 4 quarters.
Seven Eight Capital's Aerie Pharmaceuticals position peaked at $2.26M in Q1 2019.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Seven Eight Capital's 13F filing for Q2 2019, filed 12 Aug 2019.